{"id":"W4398256251","doi":"10.1158/1535-7163.mct-23-0564","title":"PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; National Institutes of Health; Susan G. Komen; Golfers Against Cancer; Cancer Prevention and Research Institute of Texas; Breast Cancer Research Foundation; Pfizer; Robert and Janice McNair Foundation; Susan G. Komen for the Cure","keywords":"Palbociclib; Gemcitabine; Breast cancer; Cancer research; Estrogen receptor; Cancer; Tamoxifen; Medicine; Internal medicine; Biology; Oncology; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002394035,0.0004322446,0.0006259494,0.0002709876,0.00005421392,0.00003633929,0.0001162252,0.0001671698,0.0002064718],"category_scores_gemma":[0.000006850512,0.000362358,0.0002251786,0.0005127311,0.0002311779,0.00007958041,0.00002930473,0.0001908212,0.000001776926],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001091957,"about_ca_system_score_gemma":0.0009836067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001488181,"about_ca_topic_score_gemma":0.0001410155,"domain_scores_codex":[0.9979921,0.0001140185,0.0004559137,0.0006376834,0.0002966788,0.000503597],"domain_scores_gemma":[0.9989706,0.0001594863,0.0001092274,0.0004459181,0.0001687845,0.0001460194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03305874,0.000431687,0.01032805,0.001586752,0.003008809,0.0001741202,0.007675028,0.0001827468,0.6909646,0.0008369096,0.0001084206,0.2516442],"study_design_scores_gemma":[0.01553471,0.002147394,0.04988849,0.004312242,0.001661924,0.0001906113,0.0006711002,0.004851228,0.2506216,0.008608978,0.6600329,0.00147879],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7095473,0.2660738,0.003448389,0.01734625,0.0004136779,0.001849714,0.001090511,0.0001213298,0.0001090088],"genre_scores_gemma":[0.9884751,0.003179417,0.002310712,0.003287631,0.0001500404,0.001078765,0.000009754871,0.0001579211,0.0013506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6599245,"threshold_uncertainty_score":0.9998828,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0195323455154225,"score_gpt":0.3185785255817443,"score_spread":0.2990461800663218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}